Edgewise to begin Phase 2 trials for muscular dystrophy drug this year
BOULDER — Edgewise Therapeutics Inc. (Nasdaq: EWTX), a clinical-stage biopharmaceutical company developing drugs to treat muscular dystrophy, reported a $14.7 million net loss in the first quarter of 2022 as it prepares to enter Phase 2 trials for its leading drug candidates. That’s up 15.7% year-over-year.
Edgewise, which is pre-revenue, reported an 11% year-over-year increase in research and development expenses, from $9.1 million to $11.1 million.
The company has $265.8 million in cash and equivalents on hand, which it says can sustain its operations through 2024.
SPONSORED CONTENT
BOULDER — Edgewise Therapeutics Inc. (Nasdaq: EWTX), a clinical-stage biopharmaceutical company developing drugs to treat muscular dystrophy, reported a $14.7 million net loss in the first quarter of 2022 as it prepares to enter Phase 2 trials for its leading drug candidates. That’s up 15.7% year-over-year.
Edgewise, which is pre-revenue, reported an 11% year-over-year increase in research and development expenses, from $9.1 million to $11.1 million.
The company has $265.8 million in cash and equivalents on hand, which it says can sustain its operations through 2024.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
BOULDER — Even with the COVID-10 pandemic several years in the rearview mirror, it remains…
-
LOVELAND — The Stinging Nettle has taken up residence in downtown, filling a hole recently…
-
Boulder Community Health this month became the first facility in Colorado to offer patients a…
-
Nextera Healthcare LLC and ImagineMD have combined to form a single direct-primary-care organization for employer…
